FORM	4
------	---

Check this box if no	,
longer subject to	
Section 16. Form 4	or
Form 5 obligations	
may continue. See	
Instruction 1(b).	

(Print or Type Peopo

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB APPROVAL OMB Number: 3235-0287 Estimated average burden hours per response... 0.5

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

(Print or Type Responses)			1									
1. Name and Address of Rep Duncan Gregory Scott	2. Issuer Name and Ticker or Trading Symbol Virios Therapeutics, Inc. [VIRI]						5. Relationship of Reporting Person(s) to Issuer (Check all applicable) X Director 10% Owner					
(Last) (F C/O VIRIOS THERAN MILTON AVENUE	^{°irst)} PEUTIC	(Middle) S, INC., 44	3. Date of Earliest Transaction (Month/Day/Year) 04/05/2021					X_Officer (give title below) Other (specify below) Chief Executive Officer				
^{(St} ALPHARETTA, GA 3	4. If Amendment, Date Original Filed(Month/Day/Year) 04/06/2021						6. Individual or Joint/Group Filing(Check Applicable Line) _X_Form filed by One Reporting Person Form filed by More than One Reporting Person					
(City) (S	State)	(Zip)	Table I - Non-Derivative Securities Acquir						red, Disposed of, or Beneficially Owned			
1.Title of Security (Instr. 3)		Date (Month/Day/Year)	Execution Date, if			4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		d of (D)	Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) Owned Form Direct		 7. Nature of Indirect Beneficial (D) Ownership (Instr. 4) 	
				Code	v	Amount	(A) or (D)	Price		(I) (Instr. 4)	(Instr. 4)	
Common Stock		04/05/2021		Р		15,675 (<u>1</u>)	А	\$ 6.1727	19,579	D		

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

SEC 1474 (9-02)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned

	(e.g., puts, calls, warrants, options, convertible securities)															
1. Title of	2.	3. Transaction	3A. Deemed	4.		5.		6. Date Exer	cisable	7. Tit	le and	8. Price of	9. Number of	10.	11. Nature	
Derivative	Conversion	Date	Execution Date, if	Transacti	on	Numl	Number and Expiration Date A		Amount of		Derivative	Derivative	Ownership	of Indirect		
Security	or Exercise	(Month/Day/Year)	any	Code		of	of (Month/Day/Year) U		Unde	rlying	Security	Securities	Form of	Beneficial		
(Instr. 3)	Price of		(Month/Day/Year)	(Instr. 8)		Deriv	ative			Securities (Instr.		(Instr. 5)	Beneficially	Derivative	Ownership	
	Derivative					Secur	urities		(Instr. 3 and			Owned	Security:	(Instr. 4)		
	Security					Acqu	ired			4)			Following	Direct (D)		
						(A) o	r						Reported	or Indirect		
						Dispo							Transaction(s)	(I)		
						of (D							(Instr. 4)	(Instr. 4)		
						(Instr	· · · ·									
						4, and	15)									
											Amount					
								Data	Emination		or					
								Date Expir Exercisable Date	Expiration Ti		Title	Number				
								Exercisable	Date		of					
				Code	V	(A)	(D)				Shares					

Reporting Owners

	Relationships						
Reporting Owner Name / Address	Director	10% Owner	Officer	Other			
Duncan Gregory Scott C/O VIRIOS THERAPEUTICS, INC. 44 MILTON AVENUE ALPHARETTA, GA 30009	Х		Chief Executive Officer				

Signatures

/s/ Greg Duncan	04/06/2021
**Signature of Reporting Person	Date

Explanation of Responses:

- * If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) This purchase was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 25, 2021.

Remarks:

This amendment relates solely to revising the footnote to clarify that the purchase was made pursuant to a Rule 10b5-1 plan.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.